Evidence map›Paper›PMID 42286441›Full record

ArticleCancer medicine2026

RETRACTION: PLK2 Phosphorylates and Inhibits Enriched TAp73 in Human Osteosarcoma Cells.

Abstract readRetraction Notice
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

retractionZ. B. Hu, X. H. Liao, Z. Y. Xu, X. Yang, C. Dong, A. M. Jin and H. Lu, "PLK2 Phosphorylates and Inhibits Enriched TAp73 in Human Osteosarcoma Cells," Cancer Medicine 5, no. 1 (2016): 74-87, https://doi.org/10.1002/cam4.558. The above article, published online on 02 December 2015 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Stephen Tait; and John Wiley and Sons Ltd. The retraction has been agreed upon following concerns raised by a third party. An investigation identified the duplication of bands within Figure 3F. Further duplications were observed between panels presented in Figure 8. An additional duplication was observed between the IB TAp73, 15 μg/mL Cis bands shown in Figure 2A and bands presented in another article published elsewhere by some of the same authors. In this case, the duplicate bands are shown to represent different proteins. The authors were contacted for their comments and supporting data but did not respond. The editors consider the results and conclusions to be compromised. The authors did not respond to our notice of retraction.

Identifiers

PMID42286441
PMCPMC13263157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.